Impilo is a privately held drug discovery and development company focused on a novel approach to enable nucleic acid-based medicines to effectively treat solid tumor cancers. The Company was founded by scientists and executives with deep experience and commitment to enable cancer patients to benefit from this important emerging drug class. The TPN Platform™ provides a tumor-targeted tissue penetration capability to specifically enhance nucleic acid drug delivery to tumors. The Company is advancing internal programs and partnering efforts towards the clinic that hold potential to address unmet needs for solid tumor cancer patients.